Zimmer Biomet to announce Q2 2026 results on August 5

0 min read     Updated on 13 Jul 2026, 06:02 PM
scanx
Reviewed by
Riya DScanX News Team
AI Summary

Zimmer Biomet Holdings, Inc. announced it will release its Q2 2026 financial results on August 5, 2026. A news release will be issued at 6:30 a.m. ET, followed by a conference call at 8:30 a.m. ET. Access is available via webcast or telephone.

powered bylight_fuzz_icon
45491534

*this image is generated using AI for illustrative purposes only.

Zimmer Biomet Holdings, Inc. will release its second quarter 2026 financial results on August 5, 2026, providing investors with an update on its performance as a global medical technology leader. The company will issue a news release detailing the quarterly results at 6:30 a.m. ET, followed by a live conference call and webcast at 8:30 a.m. ET to discuss the findings.

Conference Call Details

The earnings conference call will be accessible via a live audio webcast on Zimmer Biomet's Investor Relations website. A replay of the webcast will be available following the conclusion of the call. Investors and analysts can also participate via telephone.

Dial-in Information

Region Phone Number Conference ID
U.S. and Canada (800) 330-6710 7090861
International +1 (213) 279-1505 7090861

Zimmer Biomet designs and produces orthopedic reconstructive products, sports medicine, biologics, extremities and trauma products, and office-based technologies. The company operates in over 25 countries with sales in more than 100 countries.

What key performance indicators will investors focus on during the Q2 2026 earnings call?

How might Zimmer Biomet's global operations impact its Q2 2026 financial results?

What strategic initiatives could Zimmer Biomet highlight to drive future growth?

like15
dislike

BMO Capital initiates coverage on Zimmer Biomet with $95 target

0 min read     Updated on 09 Jul 2026, 10:55 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

BMO Capital analyst Vik Chopra has initiated coverage on Zimmer Biomet Holdings with a Market Perform rating and a price target of $95.

powered bylight_fuzz_icon
45163502

*this image is generated using AI for illustrative purposes only.

BMO Capital analyst Vik Chopra has initiated coverage on Zimmer Biomet Holdings with a Market Perform rating and a price target of $95. The rating provides a benchmark for the stock's performance relative to the broader market expectations.

Analyst Details

The coverage initiation was led by Vik Chopra of BMO Capital. The assessment categorizes Zimmer Biomet Holdings as a market performer, suggesting the stock is expected to perform in line with the market.

Price Target

BMO Capital has set a specific price objective for the company's shares.

Metric Value
Price Target $95

What key factors could drive Zimmer Biomet's stock to outperform the $95 price target?

How might recent product launches or pipeline developments influence future analyst ratings?

What are the potential risks to Zimmer Biomet's market performance in the current economic climate?

like15
dislike

More News on Zimmer Biomet Holdings Inc

Must Read Next

Earnings

Corporate Actions

Stocks